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ABSTRACT
Background    Head and neck squamous cell carcinoma 
(HNSCC) is increasing in prevalence as society ages 
worldwide. However, there are no established treatment 
protocols for elderly patients, and the threshold for defin-
ing “elderly” is undetermined. In this study, we catego-
rized elderly patients (65 years and older) with HNSCC 
into 2 groups: “young-old,” from 65 to 74 years old, and 
“old-old,” 75 years and older, and compared their treat-
ment outcomes.
Methods    The subjects were 182 patients aged 65 
years and older who visited our hospital for HNSCC 
from 2003 to 2009. We categorized them into 2 groups, 
young-old (65−74 years) and old-old (75 years and older), 
and compared the male-female ratio, ratio with underly-
ing diseases, primary tumor sites, disease stage, applied 
treatments and curative rate. Additionally, for the cura-
tive treatment category in both groups, we compared 
recurrence rate, relationship between recurrence rate and 
use of concomitant chemotherapy, the 5-year relapse-
free survival and the 5-year cause-specific survival.
Results    The ratio of patients with underlying diseases 
in the old-old group was significantly higher than in the 
young-old group, but there was no significant difference 
in curative rate between the 2 (old-old, 81.9%; young-
old, 82.7%). The 5-year, cause-specific survival in cura-
tive treatment category was significantly lower in the 
old-old (66.1%) group than the young-old (94.1%) group.
Conclusion    Elderly patients of all ages should posi-
tively receive curative treatment. We suppose that con-
comitant chemotherapy is not acceptable in elderly 
patients. The 5-CSS of the curative treatment category 
in the old-old patients was significantly lower than in the 
young-old patients.
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Globally, the population is rapidly aging and conse-
quently the prevalence of patients with head and neck 
squamous cell carcinoma (HNSCC) is increasing. HN-
SCC is not a rare disease among elderly patients, as a 
previous study reported that the number of patients with 
HNSCC is increasing among patients aged 50 and older, 
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and that 20% of HNSCC patients are aged 75 and older.1 
We thus have more and more opportunities to conduct 
treatment decisions in elderly patients. However, the 
variety of such treatments is restricted in the elderly due 
to physical issues such as decreased organ function and 
increased prevalence of underlying diseases, as well as 
psychological and societal problems such as impaired 
cognition, tendency to accept death and the nearly abso-
lute necessity of societal and financial supports. A sepa-
rate issue is that no studies have clarified the threshold 
age defining “elderly.” A number of previous articles 
have used cutoff ages of 70 or 75 years.2–7
 In Japan, individuals aged 65 and older are referred 
to as “elderly.” The ratio of elderly people to the total 
population in Japan was 25.1% in April 2014, while the 
proportion of individuals aged 75 years and older was 
12.3%.8 Both ratios are increasing. The same census 
found that in Tottori Prefecture (the location of our 
hospital), the ratio of elderly people to the total prefec-
tural population was 28.2% and the ratio of those aged 
75 years and older was 15.6%. Thus the population of 
Tottori Prefecture is aging more rapidly than Japan as a 
whole.
 This study compared the treatment outcomes of 
elderly patients aged 65 and older seen at our hospital 
for HNSCC. We classified the patients into 2 groups: 
the young-old group, aged 65−74, and the old-old group, 
aged 75 and older. 
 
MATERIALS AND METHODS
This study analyzed 182 patients aged 65 and older who 
visited our hospital for HNSCC from 2003 to 2009. 
First, we divided the patients into 2 groups based on the 
patients’ ages at their initial visits: the young-old group, 
aged 65 to 74 years, and the old-old group, aged 75 years 
and older.
 We compared the male-female ratio, ratio of patients 
with underlying diseases, primary tumor sites, disease 
stage, applied treatments and curative rate. Underlying 
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diseases were defined as conditions that could affect tu-
mor treatment, such as cardiovascular disease, diabetes, 
cerebrovascular disease, respiratory disease, hepatic dis-
ease, kidney disease and psychiatric disorders. Patients 
with at least one of these disease types were considered 
to have an underlying disease.
 Primary tumor sites were classified as larynx, oral 
cavity, hypopharynx, or others (epipharynx, orophar-
ynx, acoustic organ, paranasal sinus and salivary gland), 
while tumor stage was classified as either early tumor 
(Stage I or II) or advanced tumor (Stage III or IV), ac-
cording to the fifth edition of the Union for International 
Cancer Control classification of malignant tumors. 
 In our protocol, curative treatments were categorized 
as radiotherapy alone, surgery alone, or the combination 
of surgery and radiotherapy. Concomitant chemotherapy 
for curative treatments was classified as 4 patterns: neo-
adjuvant chemotherapy before surgery; neoadjuvant con-
current chemoradiotherapy before surgery; adjuvant con-
current chemoradiotherapy after surgery; and concurrent 
chemoradiotherapy alone. Chemotherapy dosages were 
decreased in patients aged 70 years or older or in those 
whose creatinine clearance was lower than 50 mL/min. 
Further, chemotherapy was not conducted in patients 
whose creatinine clearance was lower than 30 mL/min.
 For both the young-old and old-old groups, we in-
vestigated the prevalence of patients in each of the fol-
lowing three categories: curative treatment category, in 
which patients received curative treatment and achieved 
locoregional control; palliative treatment category, in 
which patients received palliative treatment because they 
had distant metastasis at their initial visit or could not 
tolerate further curative treatments, or in which distant 
metastasis developed during treatment; and no-treatment 
Table 1. Male-female ratio and the percentage of pa-
tients with underlying diseases 
  Group
 Young-old Old-old
 [n = 110]  [n = 72] 
 Male:female ratio 92:18 55:17
 (5.1:1)  (3.2:1) 
Patients with underlying diseases 
     Number (%) 64 (58.2%)  55 (76.2%) 
Table 2. Primary tumor site
  Group
 Young-old Old-old
 [n = 110]  [n = 72] 
 Larynx 43 (39.1%)  30 (41.7%) 
Oral cavity 18 (16.4%)  17 (23.6%) 
Hypopharynx 35 (31.8%)  11 (15.3%) 
Others 14 (12.7%)  14 (19.4%) 
 Others: epipharynx, oropharynx, acoustic organ, paranasal sinus 
and salivary gland. 
Table 3. Disease stage
  Group
 Young-old Old-old
Stage [n = 110]  [n = 72] 
 Early (I–II)  51 (46.4%)  32 (44.4%) 
Advanced (III–IV)  59 (53.6%)  40 (55.6%) 
Table 4. Applied treatments
  Group
 Young-old Old-old
Treatment [n = 110]  [n = 72] 
 Radical treatment  91 (82.7%)  59 (81.9%) 
     Radiotherapy 25 18
     Surgery 35 28
     Surgery + radiotherapy 31 13
Palliative treatment  14 (12.7%)    8 (11.1%) 
No treatment    5 (4.5%)    5 (6.9%)
category, in which no treatment was conducted due to 
patient refusal. We also examined the relationship be-
tween the frequency of underlying diseases and the cu-
rative rate.
 Next, we investigated the recurrence rate, prevalence 
of concomitant chemotherapy use, relationship between 
recurrence rate and use of concomitant chemotherapy, 
the 5-year relapse-free survival (RFS) and the 5-year 
cause-specific survival (CSS) in the curative treatment 
category in each group.
 The study was approved by the Ethics Committee of 
Tottori University Faculty of Medicine (approval number 
2594).
 When comparing the 2 groups, we used the chi-
squared and Fisher’s exact test. We calculated the 5-year 
RFS and CSS using the Kaplan-Meier method, and de-
tected the significant differences between groups using 
the log-rank test. A P value smaller then 0.05 was con-
sidered statistically significant.
RESULTS 
Male-female ratio and ratio of patients with under-
lying diseases 
Table 1 shows the male-female ratio and the ratio of 
patients with underlying diseases. The young-old group 
comprised 110 patients with a mean age of 69.5 years 
(65–74 years) and a male-female ratio of 5.1 (92 male, 18 
female). The old-old group comprised 72 patients with a 
mean age of 80.0 years (75–93 years) and a male-female 
ratio of 3.2 (55 male, 17 female). The percentage of pa-
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Table 5. Relationship between the existence of under-
lying disease and cure rate 
  Group
Underlying Young-old [n = 110] Old-old [n = 72]
disease  Curative rate   P value Curative rate   P value
 Positive 50/64 (78.6%)   44/55 (80.0%) 
  0.132  0.355 
Negative 41/46 (89.1%)   15/17 (88.2%) 
tients with underlying diseases was significantly higher 
in the old-old group (76.4%, 55 of 72 patients) than in 
the young-old group (58.2%, 64 of 110 patients) (P = 
0.012). 
Primary tumor sites and disease stage 
As shown in Table 2, the primary tumor sites in the 
young-old group (110 patients) were: larynx (43 patients, 
39.1%), hypopharynx (35 patients, 31.8%), oral cavity 
(18 patients, 16.4%) and others (14 patients, 12.7%). In 
the old-old group (72 patients) the sites were: larynx 
(30 patients, 41.7%), hypopharynx (11 patients, 15.3%), 
oral cavity (17 patients, 23.6%) and others (14 patients, 
19.4%). Table 3 shows that in the young-old group, 51 
patients (46.4%) were early stage (I or II) and 59 patients 
(53.6%) were advanced stage (III or IV). In the old-old 
group, 32 patients (44.4%) were early stage and 40 pa-
tients (55.6%) were advanced stage. 
Applied treatments 
Table 4 shows the details of the applied treatments in 
each category. The curative treatment category com-
prised 91 of 110 patients (82.7%) in the young-old group 
and 59 of 72 patients (81.9%) in the old-old group. The 
palliative treatment category comprised 14 of 110 pa-
tients (12.7%) in the young-old group and 8 of 72 patients 
(11.1%) in the old-old group. The no treatment category 
comprised 5 of 110 patients (4.5%) in the young-old and 
5 of 72 patients (6.9%) in the old-old group.
Fig. 2. In the curative treatment category, the difference between 
the 5-year CSS of the young-old group (94.1%) and old-old group 
(66.1%) was significant (**P = 0.0016). CSS, cause-specific sur-
vival.
Fig. 1. In the curative treatment category, the difference between 
the 5-year RFS of the young-old group (76.4%) and old-old 
group (61.3%) was significant (*P = 0.027). RFS, relapse-free 
survival.
Table 6. Number of recurrent patients
  Group
 Young-old  Old-old 
Recurrent patients [n = 91] [n = 59] P value

















































Relationship between underlying disease and cu-
rative rate
Table 5 shows the curative rates in patients with or with-
out underlying diseases. In both groups, curative treat-
ments were possible in a higher percentage of patients 
without underlying diseases than in those who had such 
conditions: in the young-old group, 89.1% versus 78.1%, 
and in the old-old group, 88.2% versus 80.0%. In each 
group, the curative rate of patients without underlying 
diseases was slightly higher but not significantly so.
Frequency of recurrence
Table 6 shows the number of patients who developed re-
currence in the curative treatment category. Recurrence 
occurred in 18 of 91 patients (19.8%) in the young-old 
group and 19 of 59 patients (32.3%) in the old-old group. 
The recurrence rate was higher in the old-old group than 
the young-old group, but the difference was not signifi-
cant. 
Relationship between use of concomitant chemo-
therapy and recurrence rates 
The percentage of the curative treatment category in 
which concomitant chemotherapy was performed was 
significantly higher in the young-old group than in the 
old-old group: 58.2% (53 of 91 patients) versus 40.7% (24 
of 59 patients), respectively (P = 0.035). In both groups, 
the recurrence rates were higher when concomitant 
chemotherapy was used than when it was not, but not 
significantly so: in the young-old group, 26.4% (14 of 53 
patients) versus 10.5% (4 of 38 patients), and in the old-
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old group, 33.3% (8 of 24 patients) versus 31.4% (11 of 
35 patients), respectively. 
Survival rate (5-year RFS and CSS) 
As shown in Fig. 1, the 5-year RFS of the curative treat-
ment category in the young-old group (91 patients) was 
76.4%, while that in the old-old group (59 patients) was 
61.3%, a significant difference (P = 0.027). As shown in 
Fig. 2, the 5-year CSS of the curative treatment category 
in the young-old group (91 patients) was 94.1%, while 
that in the old-old group (59 patients) was 66.1%, a sig-
nificant difference (P = 0.0016).  
  
DISCUSSION
The treatment decision was dedicated to elderly patients 
because of their physical or social circumstances. In 
our study, we investigated the outcomes of treatment for 
HNSCC in elderly patients.
 Prior studies reported that increased patient age was 
associated with a significantly higher ratio of females to 
males,2, 9 and our results showed a similar trend. In ad-
dition, the prevalence of larynx and oral cavity tumors 
was found to be higher in older patients while that of hy-
popharynx tumors was lower,2, 9, 10 which mirrored our 
findings. 
 Regarding the ratio of early- to advanced-stage tu-
mors, various results have been reported. For example, 
one study found that in patients aged 75 years and older, 
this ratio did not differ greatly between elderly and 
young adult patients.2 Another study reported that el-
derly patients had more early-stage tumors than younger 
patients.4 In our study, advanced-stage tumors were 
observed slightly more often than early-stage tumors in 
both groups.
 Derks et al. reported that in 3 patients groups divid-
ed by age (ages 45−60, 70−79 and 80 years and older), 
the percentages of patients who received curative treat-
ment were 89%, 75% and 36%, respectively.3 Huang et 
al.4 reported that patients under 75 years old and those 
75 years and older received curative treatment in 93% 
and 79% of patients, respectively. As shown in these 
reports, older patients were less likely to be candidates 
for curative treatments. In our study, the percentages of 
patients in the curative treatment category were 82.7% in 
the young-old group and 81.9% in the old-old group. 
 The percentages of patients with underlying diseases 
were 58.2% in the young-old group and 76.2% in the 
old-old group. However, there were no significant cor-
relations between the existence of underlying disease 
and the curative rate, and curative treatments can often 
be conducted despite the presence of these conditions. 
One previous study reported that the presence of under-
lying diseases did not affect treatment completion,11 and 
another found that there was no correlation between the 
existence of underlying disease and either co-morbidity 
or complications in elderly patients.12 As reported in 
some studies,2, 3, 6, 13 treatment choices in elderly patients 
with HNSCC should not be based on patients’ ages. We 
suppose that both young-old and old-old patients can 
achieve nearly equivalent curative rates as a result of cu-
rative treatments.
 In our study, the use of concomitant chemotherapy 
did not diminish the recurrence rate in either group, 
although the recurrence rate tended to be higher in 
the old-old group than the young-old group. Previous 
studies reported that reducing chemotherapy dosages 
undermined the effectiveness of treatments 14 and that 
the concomitant use of chemotherapy did not suppress 
local tumor recurrence or distant metastasis.15 We sup-
pose that concomitant chemotherapy is not acceptable 
in elderly patients, since chemotherapy doses must be 
reduced in most of them. 
 It was reported that the survival rate was lower 
or almost equivalent in an elderly group compared to 
a younger group.9 In our study, the 5-year RFS of the 
curative treatment category in the young-old group was 
76.4%, which was significantly higher than the 61.3% in 
the old-old group. Further the 5-year CSS of the curative 
treatment category in the young-old group was 94.1%, 
which was significantly higher than the 66.1% in the old-
old group.
 In conclusion, elderly patients of all ages should 
absolutely receive curative treatment. We believe that 
concomitant chemotherapy is not acceptable in elderly 
patients. The 5-CSS of the curative treatment category 
in the old-old patients was significantly lower than in the 
young-old patients. 
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